Nuvectis Pharma's Market Cap Surges US$18m: Retail Investors and Insiders Benefit

Nuvectis Pharma's market cap rose $18m last week, benefiting retail investors who hold 44% of the company and insiders who own 40% of the profits. Institutional ownership is present, with a respectable stake held by institutions, although there is a risk of a "crowded trade." The top 11 shareholders own 50% of the company.